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Introduction
Lung cancer is the most-common cause of loss of 
productivity and life, as it leads to premature cancer-related 
mortality (1-3). Furthermore, most cases of lung cancer are 
detected at an old age, resulting in poor prognosis (4). Early 
detection may allow treatment at early stages and improve 
the prognosis of lung cancer. Although some randomized 
clinical trials showed unsuccessful results of low-dose 
computed tomography for lung-cancer screening (5), recent 
studies have revealed that it can detect lung cancer early and 
thereby reduce mortality (6,7). Moreover, computer-aided 
detection systems have reduced the errors and false-negative 
rates, improved detection rate, and diagnosed lung cancer 
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more efficiently (8,9). Therefore, early detection of lung 
cancer can be frequently conducted, allowing management 
of early stage lung cancer. However, thus far, there is no 
consensus on the post-operative management of stage IB 
non-small cell lung cancer (NSCLC).
On the basis of the results of a previous meta-analysis (10), 
an international trial was conducted to determine the 
effects of adjuvant chemotherapy in lung cancer. The trial 
showed that cisplatin-based adjuvant chemotherapy improves 
survival of NSCLC in patients who underwent complete 
resection surgery (11). Following this trial, several studies 
have been conducted on stage IB NSCLC: some reported 
positive effects of adjuvant chemotherapy (12,13), whereas 
others reported negative effects (11,14,15). Strauss et al. 
showed that adjuvant chemotherapy had a positive effect 
on patients with stage IB tumors measuring >4 cm (16). 
In addition, the recent National Comprehensive Cancer 
Network (NCCN) guidelines stated that adjuvant chemotherapy 
can be used for patients with stage IB NSCLC having high-risk 
factors such as poorly differentiated tumor, vascular invasion, 
wedge resection, tumor size >4 cm, visceral pleural invasion, 
and incomplete lymph node (LN) sampling (17). However, the 
evidence to support this guideline is insufficient.
Therefore, this study aimed to identify the predictive 
factors for prognosis of stage IB NSCLC and to determine 
the efficacy of adjuvant chemotherapy on recurrence and 
survival in patients with stage IB NSCLC, especially in 
high-risk patients.
Methods
Study population
We analyzed 1,316 patients who underwent thoracic surgery 
at Gangnam Severance Hospital from Jan 2005 to Dec 2014. 
A total of 556 patients were diagnosed with lung cancer, 
of which 90 patients with stage IB NSCLC were enrolled. 
All the patients underwent one of the following definite 
complete resection surgeries: wedge resection, lobectomy, 
or pneumonectomy with systematic LN dissection. 
Exclusion criteria were as follows: serious comorbidity 
that could influence survival such as other cancers, 
synchronous lung cancer (two or more histologically 
distinct simultaneously detected malignancies), and small 
cell lung cancer (SCLC). After exclusion of one patient with 
synchronous lung cancer, 89 patients were finally recruited 
in this study. The requirement of patients’ informed 
consent was waived owing to the retrospective nature of the 
study by the Institutional Review Board (IRB) of Gangnam 
Severance Hospital (number: 3-2016-0276).
Adjuvant chemotherapy
We defined adjuvant chemotherapy as post-operative 
chemotherapy involving the use of platinum-based agents; 
the therapy regimen was selected by respective clinicians. 
Most regimens included cisplatin (75 mg/m2), carboplatin 
combined with vinorelbine (25 mg/m2), or paclitaxel. 
Usually, 4 cycles of chemotherapy were performed using 
these regimens, and there was no definite indication of 
adjuvant therapy. Although the follow-up schedule varied, 
usually, chest computed tomography was performed every 
3–6 months for the first 2 years, followed by once every 
6–12 years. If recurrence was suspected, integrated positron 
emission tomography-computed tomography was performed.
Pathologic analysis
For histopathologic analysis, two pathology specialists 
reviewed all the samples of patients, independently. They 
had no knowledge of those patients’ clinical outcomes. 
A decision was made on the basis of 2015 World Health 
Organization classification (18). If they have different 
opinions, they met, discussed, and reached a final diagnosis 
by consensus. Hematoxylin and eosin staining was 
performed for all samples, and additional staining was 
performed, when needed, according to the decisions of 
the pathology specialist. Lymphovascular invasion (LVI) 
was defined as the presence of tumor cells or emboli in 
the lymphatic or blood vessel lumen (19). Visceral pleural 
invasion (VPI) was defined as the presence of any distortion 
of the pleural elastic layer caused by malignant cells (20).
Definition of terms
As per the NCCN guidelines, high-risk patients were 
defined as those with poorly differentiated tumors, wedge 
resection, vascular invasion, tumor size >4 cm, VPI, 
and incomplete LN sampling. However, as only two 
patients underwent wedge resection and none underwent 
incomplete LN sampling, these two factors could not be 
included in this study. Therefore, after elimination of these 
factors, we defined high-risk patients as those with poorly 
differentiated tumors, vascular invasion, tumor size >4 cm, 
and VPI. Disease-free survival (DFS) was defined as the 
period between the date of resection surgery and the date of 
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recurrence, death, or the last date on which the patient was 
known to be alive. Overall survival (OS) was defined as the 
period between the surgery date and the death or the last 
date on which the patient was known to be alive. 
Statistical analysis
The t-test and chi-square test were used to compare 
continuous variables and categorical variables between the 
two groups, respectively. All univariate and multivariate 
analyses for DFS and OS were performed using the Cox 
regression models. However, univariate analysis for survival 
curve was performed using the Kaplan-Meier method and 
the log-rank test. For the multivariate analysis, we used all 
the parameters included in this study as covariates, except 
the pathologic type of NSCLC (because the statistical value 
was immeasurable in univariate analysis) and predominant 
type (because of many missing values, as it was applicable 
only to the adenocarcinoma type). All P values <0.05 were 
considered statistically significant.
Results
Clinical characteristics of subjects 
Among the  89  sub jec t s ,  27  underwent  ad juvant 
chemotherapy. The adjuvant chemotherapy group had 
more elderly patients (>65 years) (40.7%) than the control 
group who did not undergo adjuvant chemotherapy (64.5%, 
P=0.037). The control group had more patients with 
squamous cell lung cancer (40.3%), whereas the adjuvant 
chemotherapy group more patients with adenocarcinoma 
lung cancer (74.1%, P=0.002). There was no significant 
difference in the sex, operation type, tumor size, 
predominant type, differentiation, VPI, LVI, and perineural 
invasion between the control and adjuvant chemotherapy 
groups (Table 1).
Univariate analyses for DFS and OS
We tried to find any significant factors for survival using Cox-
regression. Age, sex, operation type, size, pathologic type, 
predominant type, LVI, perineural invasion, and adjuvant 
chemotherapy was not significant predictive factor for DFS 
and OS. However, among all the factors analyzed, only VPI 
was a significant risk factor for DFS [hazard ratio (HR): 7.051; 
95% confidence interval (CI): 1.570–31.659; P=0.011) and 
OS (HR: 8.289; 95% CI: 1.036–66.307; P=0.046) (Table 2).
Effect of adjuvant chemotherapy on DFS and OS according 
to the adjuvant chemotherapy
Kaplan-Meier survival analysis did not show any significant 
difference in DFS (P=0.662) and OS (P=0.866) between 
the two groups (Figure 1). We tried various combinations 
of factors to determine whether adjuvant chemotherapy is 
a significant predictor of survival. However, combinations 
of age, pathologic type, VPI, and etc., did not show any 
significant effect of adjuvant chemotherapy on DFS and OS 
(data are not shown).
Some patients were classified as high-risk patients 
(19.1% with poorly differentiated tumor, 27.0% with LVI, 
28.1% with tumor size >4 cm, and 51.7% with VPI) as per 
the NCCN guideline definitions. However, even in these 
patients, adjuvant chemotherapy was not a significant factor 
for DFS and OS (Table 3).
Effect of VPI on DFS and OS according to the VPI
Kaplan-Meier survival analysis showed that VPI was a 
significant factor for DFS (P=0.003) and OS (P=0.017) 
(Figure 1). Multivariate analysis of VPI for survival showed 
that after adjustment for age, VPI was a significant risk 
factor for DFS (HR: 7.528; 95% CI: 1.664–34.059; 
P=0.009) and OS (HR: 8.748; 95% CI: 1.087–70.387; 
P=0.041). After adjustment for age and sex, VPI was still 
a significant risk factor for DFS and OS. However, after 
adjustment for other covariates including pathologic type, 
operation type, tumor size, LVI, perineural invasion, and 
adjuvant chemotherapy, VPI was a significant risk factor for 
DFS, but not for OS (Table 4). 
Discussion
Although adjuvant chemotherapy is routinely performed 
for patients with stage II–III NSCLC, it has a negative 
effect on stage IA NSCLC due to its chemotoxicity 
and immunosuppressive effects (21). The effects of 
adjuvant chemotherapy on completely resected stage 
IB NSCLC are controversial: Some studies have shown 
beneficial effects of adjuvant chemotherapy (13,22,23), 
whereas others have shown non-significant effects on OS 
(12,16,24). Further, according to the NCCN guidelines, 
patients with completely resected stage IB NSCLC may 
not require adjuvant therapy, but high-risk patients may 
require chemotherapy. Moreover, in the literature, there 
are no absolute indications for adjuvant chemotherapy 
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Table 1 Clinical characteristics of enrolled subjects according to adjuvant chemotherapy
Characteristics Control (n=62), n (%) Adjuvant chemotherapy (n=27), n (%) P value
Age >65 years 40 (64.5) 11 (40.7) 0.037
Sex (male) 50 (80.6) 17 (63.0) 0.075
Operation type 0.812
Wedge resection or lobectomy 59 (95.2) 26 (96.3)
Pneumonectomy 3 (4.8) 1 (3.7)
Size >4 cm 18 (29.0) 7 (25.9) 0.731
Pathologic type 0.002
Adenocarcinoma 35 (56.5) 20 (74.1)
Squamous cell 25 (40.3) 2 (7.4)
Adenosquamous cell 0 (0.0) 2 (7.4)
Other* 2 (3.2) 3 (11.1)
Predominant type
§
0.129
Lepidic 2 (5.6) 0 (0.0)
Acinar 23 (63.9) 9 (45.0)
Papillary 4 (11.1) 8 (40.0)
Micropapillary 4 (11.1) 2 (10.0)
Solid 3 (8.3) 1 (5.0)
Differentiation** 0.430
Well differentiation 5 (8.1) 1 (3.8)
Moderate differentiation 47 (75.8) 18 (69.2)
Poorly differentiation 10 (16.1) 7 (26.9)
Visceral pleural invasion 31 (50.0) 15 (55.6) 0.630
Lymphovascular invasion 15 (24.2) 9 (33.3) 0.372
Perineural invasion 3 (4.8) 1 (3.7) 0.801
Data are presented as mean ± SD or percentage. *, other includes pleomorphic carcinoma, large cell carcinoma, mucoepidermoid 
carcinoma (n=2), and large cell neuroendocrine carcinoma; **, one datum is missing in the “Adjuvant chemotherapy” group; 
§
, predominant 
type was assessed only in adenocarcinoma lung cancer and pleomorphic carcinoma.
of completely resected stage IB NSCLC. With an aim 
to determine the effects of adjuvant chemotherapy on 
stage IB NSCLC, the present study showed that adjuvant 
chemotherapy does not have any significant benefits for 
stage IB NSCLC, even for high-risk patients. 
The NCCN guidelines recommend that poorly 
differentiated tumors, LVI, wedge resection, tumor size 
>4 cm, VPI, and incomplete LN sampling are high-risk 
factors and can be considered when determining treatment 
with adjuvant chemotherapy. However, these factors have 
not proven to be independent factors in well-designed 
studies. Many clinicians decide to administer adjuvant 
chemotherapy on the basis of their experience and other 
recommendations for managing completely resected stage 
IB NSCLC. However, we found that these above factors 
are neither powerful for OS prognosis nor important for 
deciding whether to administer adjuvant chemotherapy. 
Therefore, adjuvant chemotherapy should be carefully 
considered for patients with completely resected stage IB 
NSCLC, and reliable detailed criteria should be established 
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Table 2 Univariate analyses for disease-free survival and overall survival
Variables
Disease-free survival Overall survival
HR 95% CI P value HR 95% CI P value
Age, years
≤65 Reference – – Reference – –
>65 1.449 0.485–4.333 0.507 1.357 0.324–5.684 0.676
Sex
Female Reference – – Reference – –
Male 0.425 0.147–1.230 0.114 0.581 0.138–2.446 0.459
Operation type
Wedge resection or lobectomy Reference – – Reference – –
Pneumonectomy 1.485 0.187–11.778 0.708 3.182 0.385–26.335 0.283
Size 
≤4 cm Reference – – Reference – –
>4 cm 2.406 0.831–6.964 0.105 1.631 0.387–6.868 0.505
Pathologic type
Adenocarcinoma Reference – – Reference – –
Squamous cell 0.149 0.019–1.168 0.070 Unmeasurable 0.960
Adenosquamous cell Unmeasurable 0.986 Unmeasurable 0.987
Etc. 2.615 0.313–21.837 0.375 7.724 0.638–93.559 0.108
Predominant type
Lepidic/acinar/papillary Reference – – Reference – –
Micropapillary/solid 0.399 0.051–3.126 0.382 0.468 0.054–4.038 0.490
Visceral pleural invasion
Absent Reference – – Reference – –
Present 7.051 1.570–31.659 0.011 8.289 1.036–66.307 0.046
Lymphovascular invasion
Absent Reference – – Reference – –
Present 1.389 0.430–4.489 0.583 1.482 0.359–6.124 0.587
Perineural invasion
Absent Reference – – Reference – –
Present 2.535 0.316–20.309 0.381 4.373 0.505–37.858 0.180
Adjuvant chemotherapy 0.749 0.204–2.750 0.663 1.130 0.273–4.684 0.866
Differentiation was unmeasurable (P=0.947–0.948). HR, hazard ratio; CI, confidence interval.
for selection of subjects.
Our study showed that VPI is a strong predictive factor 
for DFS and OS. In the 1970s, Brewer et al. reported that 
patients with VPI had a significantly poor prognosis (25); 
consistent with their findings, many studies confirmed 
that VPI is an independent factor for poor prognosis of 
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Figure 1 Disease-free survival and overall survival according to adjuvant chemotherapy (A,B) and visceral pleural invasion (C,D).
Table 3 Effects of adjuvant chemotherapy in high-risk patients
Conditions Number (%)
Disease-free survival Overall survival
HR 95% CI P value HR 95% CI P value
Poorly differentiated tumors 17 (19.1) 0.617 0.056–6.854 0.695 0.596 0.054–6.613 0.674
Lymphovascular invasion 24 (27.0) 0.407 0.042–3.932 0.437 0.689 0.062–7.639 0.761
Tumors larger than 4 cm 25 (28.1) 0.514 0.060–4.405 0.544 0.631 0.063–6.323 0.695
Visceral pleural invasion 46 (51.7) 0.497 0.105–2.345 0.377 1.154 0.210–6.334 0.869
HR, hazard ratio; CI, confidence interval.
NSCLC (26,27). Furthermore, recent studies showed that 
VPI is an adverse prognostic factor for early stage NSCLC 
(28,29). This could be because tumors with VPI are likely 
to break through the visceral pleura and lead to pleural 
intraluminal metastasis. Our current results are consistent 
with those of the above-mentioned studies. However, in 
high-risk patients with VPI, adjuvant chemotherapy did not 
significantly affect the prognosis of NSCLC. Therefore, we 
believe that VPI is a significant risk factor for prognosis, but 
not a decisive factor for adjuvant chemotherapy.
Adjuvant chemotherapy is frequently performed for young 
patients and patients with adenocarcinoma type rather than 
old patients and those with squamous cell type in this study. 
This might be because the toxicity of adjuvant chemotherapy 
is higher at an old age than at a young age. Furthermore, 
the relatively good prognosis of squamous cell lung 
1,000
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cancer might deter clinicians from administering adjuvant 
chemotherapy (30). However, the present study reported 
that tumor size, differentiation, LVI, and VPI, which are 
defined as high-risk factors in the NCCN guidelines, need 
not be considered when making a decision about adjuvant 
chemotherapy. Although many researchers rely on their own 
experience and other recommendations with insufficient 
evidence to make a decision about adjuvant chemotherapy, it 
is important to note that our data are sourced from only one 
institute (with five pulmonologists); therefore, our results 
should be carefully considered and applied.
Despite our important findings, this study had a few 
limitations. First, it included a small number of patients 
and short period, which might have yielded suboptimal 
results. Especially, subgroup analysis cannot have powerful 
credit. Then, efficacy of adjuvant chemotherapy should 
be carefully assessed. Second, we included some patients 
who had recently undergone surgery. Such inclusion could 
result in confounding findings, with a high censor rate in 
statistical analysis. Third, only two patients in our cohort 
underwent wedge resection and none of the patients 
underwent incomplete LN sampling. Therefore, we could 
not determine whether these factors are high-risk factors 
that should be considered when making a decision about 
adjuvant chemotherapy. Fourth, physicians decided adjuvant 
chemotherapy; and this bias might lead insignificant results 
of adjuvant chemotherapy. Last, we did not determine the 
amount of VPI, quantitatively. Sub-group analysis between 
focal invasion and extensive invasion will be interesting.
In conclusion, this study suggested that adjuvant 
chemotherapy may not be significantly effective for the 
treatment of patients with stage IB NSCLC, even for high-
risk patients. In addition, VPI is a strong prognostic factor 
for survival. Further long-term and multi-center prospective 
studies are required to confirm our findings.
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